The Week That Was: MRK Enters COVID Space, GSK's 1Bln Dose Target, Roche, GILD Team Up For REMDACTA

The week that just passed by saw some big names joining the race to develop vaccines for COVID-19, a couple of deals to speed up the manufacture of the vaccine and promising trial results of one of the potential COVID-19 treatments.

from RTT - Biotech https://ift.tt/3gCgKtL
via IFTTT

Read More »

Pliant Therapeutics To Debut On Nasdaq On June 3

South San Francisco, California-based Pliant Therapeutics is slated to debut on the Nasdaq Global Market, under the symbol 'PLRX', on June 3, 2020. Founded in 2016, Pliant Therapeutics is a clinical stage biopharmaceutical company developing novel therapies for the treatment of fibrosis.

from RTT - Biotech https://ift.tt/2zJGDao
via IFTTT

Read More »

Stock Alert: Canopy Growth Tumbles 18% On Earnings Miss, Uncertain Outlook

Shares of Canopy Growth Corp. (CGC, WEED.TO) are losing more than 18 percent or $3.94 in Friday's morning trade at $17.78 after the Canadian cannabis company's fourth-quarter results missed analysts' estimates. The stock has traded in a range of $9.00 to $44.17 in the past 52 weeks.

from RTT - Earnings https://ift.tt/3eu3F3O
via IFTTT

Read More »

Stock Alert: Williams-Sonoma Hits New 52-week High

Shares of Williams-Sonoma Inc. (WSM) are rising more than 10 percent or $7.61 in Friday's morning trade at $80.64, after touching a new 52-week high of $80.95 earlier as the omni-channel specialty retailer's first-quarter results trumped analysts' estimates.

from RTT - Earnings https://ift.tt/2XNiJTA
via IFTTT

Read More »

At The ASCO: ONCY, IMV, CRDF, GILD, TAK.

Here's a quick look at some of today's ASCO presentations.

from RTT - Biotech https://ift.tt/2XcJ9yG
via IFTTT

Read More »

Stock Alert: Big Lots Stock Up 15% In Premarket On Stellar Q1 Results, Strong Q2 Outlook

Shares of Big Lots Inc. (BIG) are rising over 15% in pre-market today, after the company reported stellar Q1 results and issued strong Q2 earnings outlook. The stock has been trading in the range of $10.13 - $40.10 for the past one year, and closed Thursday's trade at $36.59, down $2.43 or 6.23%. BIG is currently trading at $42.11, up $5.52 or 15.09% in the pre-market session.

from RTT - Before the Bell https://ift.tt/3clnw3T
via IFTTT

Read More »

AstraZeneca: IMFINZI Plus Tremelimumab Showed Promising Clinical Activity In HCC Patients

AstraZeneca Plc (AZN.L, AZN) said Friday that results from the global Phase II Study 22 trial testing the company's tremelimumab added to IMFINZI (durvalumab) demonstrated promising clinical activity and tolerability in patients with advanced hepatocellular carcinoma or HCC.

from RTT - Biotech https://ift.tt/3gDuqVw
via IFTTT

Read More »